Compugen Ltd (NAS:CGEN)
$ 1.57 -0.06 (-3.68%) Market Cap: 141.45 Mil Enterprise Value: 31.69 Mil PE Ratio: 52.62 PB Ratio: 2.33 GF Score: 53/100

Compugen Ltd at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 02:10PM GMT
Release Date Price: $0.8665 (+3.81%)
Stephen Willey
Stifel Financial Corp. - Analyst

Next session this morning is Compugen. Representing Compugen, we have Anat Cohen-Dayag, who is the Chief Executive Officer; Eran Ophir, who is the Chief Scientific Officer. Also in attendance, we have the new Chief Financial Officer, Alberto Sessa; and then from IR and Corporate Communications, we have Yvonne Naughton. Aran, before we get into any specific Q&A, you want to make any opening comments, or do you just want to?

Anat Cohen;Dayag
Compugen Ltd. - President & CEO

Yes. I'll just give a high-level overview about the company. We're a therapeutic-discovery and development company. We discover new drug targets, and we develop first-in-class drugs. Targeting these drug targets, focused in the field of cancer immunotherapy. We have four clinical-stage programs, four developed internally; and two are developed with -- by partners, AstraZeneca and Bayer.

And we also have an earlier stage pipeline addressing the various mechanisms of actions in the immune-suppressive tumor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot